Study Evaluating MYO-029 in Adult Muscular Dystrophy

NCT00104078 Phase 1/Phase 2 COMPLETED

The purpose of this phase I/II, multicenter, safety trial is to study MYO-029 in adult patients with muscular dystrophy.

Details

Lead sponsor	Wyeth is now a wholly owned subsidiary of Pfizer
Phase	Phase 1/Phase 2
Status	COMPLETED
Enrolment	108
Start date	2005-02
Completion	2007-01

Conditions

• Becker Muscular Dystrophy
• Facioscapulohumeral Muscular Dystrophy
• Limb-Girdle Muscular Dystrophy

Interventions

• MYO-029

Primary outcomes

• Safety assessment

Countries

United States